Tyra biosciences to host conference call on interim clinical data of tyra-300 from surf301 phase 1/2 study on october 25, 2024, at 8am et

Carlsbad, calif. , oct. 23, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, today announced that it will host a conference call and webcast on october 25, 2024 at 8:00 am et to share interim clinical results of tyra-300 from the surf301 phase 1/2 study in metastatic urothelial cancer (muc).
TYRA Ratings Summary
TYRA Quant Ranking